BBDDL2059

BBDDL2059 is a selective covalent inhibitor of histone methyltransferase EZH2 with an IC50 of 1.5 nM for EZH2-Y641F. BBDDL2059 inhibits lymphoma cell growth at nanomolar concentrations and can be used for anticancer research[1].

Product Specifications

CAS Number

[2691174-27-1]

UNSPSC

12352005

Target

Histone Methyltransferase

Type

Reference compound

Related Pathways

Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bbddl2059.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=CC(CNC(C=C)=O)=CC(N(C2CCOCC2)CC)=C1C)NCC3=C(C=C(NC3=O)C)SC

Molecular Formula

C27H36N4O4S

Molecular Weight

512.66

References & Citations

[1]Zhang Y, et.al. Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2. J Med Chem. 2023 Jun 8;66 (11) :7629-7644.